No Patents for Botanicals

Comer, Ben
June 2011
Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p32
The article focuses on the idea of restricting patents for botanicals, which are drugs made from part of a plant. Sanofi-Aventis SA's vice president Ray Jupp, says that botanicals are generally patented by process and inquired if there would be a way to trademark a plant-derived drug wherein the company is studying 12 nameless botanicals. Jupp has stressed on the difficulty of knowing the exact chemicals that are at work in a botanical combination and the challenge of its approval.


Related Articles

  • Plavix Patent Attacked. Houlton, Sarah // Pharmaceutical Executive;Mar2005, Vol. 25 Issue 3, p26 

    Reports on the pretrial proceeding that will be faced by Sanofi-Aventis SA for the patent of its blood thinning agent Plavix against Aircoat, a shell company, in New York. Plan of Apotex, a Canadian company and India's Dr Reddy on the U.S. patent of Plavix; Expiry date of Plavix's patent in the...

  • Sanofi-Aventis/Apotex: olive branch acceptance to reduce generic threat.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p14 

    The article reports on the agreement of Sanofi-Aventis and Bristol-Myers Squibb Co. to settle a patent infringement suit with Canadian generics maker Apotex over the anti-platelet agent Plavix. The settlement should delay the generic threat to Plavix as well as to enable the companies to avoid...

  • Sanofi-Aventis sued for patent violation.  // Medical Device Daily;9/7/2007, Vol. 11 Issue 171, p9 

    The article reports on the lawsuit filed by Burgdorf, Switzerland-based Ypsomed against Paris, France-based Sanofi-Aventis. Ypsomed, the contract manufacturer for insulin injection pens for Sanofi-Aventis, sued the pharmaceutical company for alleged breach of patent over the SoloSTAR line of...

  • CORPORATE.  // MondayMorning;6/1/2009, Vol. 17 Issue 20, p2 

    No abstract available.

  • News bites.  // Pharmaceutical Technology Europe;May2009, Vol. 21 Issue 5, p8 

    The article offers news briefs related to pharmaceutical industry in Germany. Sanofi Aventis SA will acquire the generics company Medley for 500 million euro and the biopharmaceutical company BiPar Sciences Inc. A study reveals that patient recruitment takes up 23% of the total clinical trial...

  • Court Provides Wiggle Room.  // BioWorld Today;11/7/2013, Vol. 24 Issue 215, p4 

    The article discusses the court case, Sanofi-Aventis v. Pfizer Inc., wherein a U.S. Federal Circuit Court has affirmed the Patent and Trademark Office's Board of Patent Appeals and Interferences' award of priority of invention to Pfizer with regards to a deoxyribonucleic acid (DNA) polynucleotide.

  • Aventis's 'poison pill' raises market concerns. Hoare, Steve // Lawyer;5/3/2004, Vol. 18 Issue 17, p5 

    Reports on debate provoked by Sanofi's takeover of Aventis among the drug companies' legal advisers about the importance of France's first poison pill that centers on the Plavix warrants, a product that would reimburse Aventis' shareholders in the event of Sanofi being unsuccessful in pending...

  • SANOFI.  // Contract Pharma;Jul/Aug2012, Vol. 14 Issue 6, p52 

    The article profiles Sanofi located in Paris, France, the number three company in the list of the top 20 pharma in the July/August 2012 issue of the journal "Contract Pharma." It says that the patent protection for Plavix was lost by Sanofi in most markets in 2012 and gained around 1.8 billion...

  • Generics line up waiting for big-name patents to expire. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p90 

    The article reports on the line up of generic drugs that are waiting for the approval given the expire of branded drugs in the U.S. The loss of the patent of sleep medication, Ambien, by Sanofi-Aventis SA has spawned the approval of 13 equivalents of zolpidem tartrate. Another cluster of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics